Cross-Sector entity
Clarity Pharmaceuticals is most often covered alongside 4D Medical, which appears in 3 of these 6 stories. That works out to roughly 1.4 stories per week across a 29-day span. The busiest single day carried 3. Coverage clusters in pharma, which accounts for 2 of those 6, with the remainder spread across 4 other categories.
6 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Clarity Pharmaceuticals is most often covered alongside 4D Medical, which appears in 3 of these 6 stories. That works out to roughly 1.4 stories per week across a 29-day span. The busiest single day carried 3. Coverage clusters in pharma, which accounts for 2 of those 6, with the remainder spread across 4 other categories. Negative sentiment appears in 0% of the tracked stories. Each carries 3.5 original sources on average. This profile follows 6 Cross-Sector stories mentioning Clarity Pharmaceuticals across the period from February 25, 2026 to March 25, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Clarity Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Phase III Milestones
Anticipated data readouts for TCT imaging agents supported by Cu-64 supply.
Supply Chain Integration
Integration of Theragenics' output into Clarity's clinical trial logistics.
Production Ramp-up
Expected commencement of large-scale isotope production for late-stage clinical trials.
Process Integration
Technical teams begin integrating manufacturing protocols and quality control standards.
Agreement Signed
Clarity and Theragenics formalize the large-scale manufacturing supply deal for Cu-64.
Reporting Season Pressure
Difficult February reports for CSL and Sonic Healthcare extend index declines.
Anteris Funding
Anteris Technologies raises approximately $440 million for heart valve technology.
Nasdaq Biotech Peak
The index records a 30% annual gain, diverging from broader tech markets.
Record Funding Year
Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
ASX Healthcare Slump
The sector begins a calendar year decline of 25% led by major heavyweights.
Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials.
Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.
Source: vietnamtribune.com · malaysiasun.com
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.
Source: 0 Comments (au) · 0 Comments (au)
